F1386-0303

Overview

F1386-0303 is a highly selective MAP4K4 inhibitor with an IC 50 of 34 nM against human targets. F1386-0303 exerts cardiomyocyte protective and function-preserving effects through mechanisms such as alleviating oxidative stress, inhibiting caspases, and maintaining mitochondrial membrane potential, while it does not interfere with the activity of Doxorubicin ( HY-15142A ) in cancer cells. F1386-0303 is rapidly cleared and has no bioavailability in mice, but it is well-suited as a tool compound for target validation. F1386-0303 can be applied to studies related to cardiac ischemia-reperfusion injury, Doxorubicin -induced cardiotoxicity, myocardial infarction and other related conditions.

Application

Products | Products > Disease Areas > Ischemia-Reperfusion Injury | Products > Disease Areas > Myocardial Infarction | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Oxidative Stress and Inflammation | Products > Disease Areas > Nervous System Injury | Products > Disease Areas > Heart Disease | Products > Signaling Pathways > MAPK/ERK Pathway | Products > Research Areas > Inflammation/Immunology | Products > Research Areas > Cardiovascular Disease | Products > Signaling Pathways > MAP4K

Product Information

• Catalog No.: HY-W207224
• CAS No.: 287177-12-2
• Molecular Formula: C18H13N3O
• Molecular Weight: 287.32
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source